Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 10—October 2019
Dispatch

Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir1

Vasiliy P. Mishin, Mira C. Patel, Anton Chesnokov, Juan De La Cruz, Ha T. Nguyen, Lori Lollis, Erin Hodges, Yunho Jang, John Barnes, Timothy Uyeki, Charles T. Davis, David E. Wentworth, and Larisa V. GubarevaComments to Author 
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (V.P. Mishin, M.C. Patel, A. Chesnokov, J. De La Cruz, H.T. Nguyen, L. Lollis, E. Hodges, Y. Jang, J. Barnes, T. Uyeki, C.T. Davis, D.E. Wentworth, L.V. Gubareva); Battelle Memorial Institute, Atlanta (M.C. Patel, J. De La Cruz, H.T. Nguyen, L. Lollis)

Main Article

Table 2

Baloxavir susceptibility of zoonotic and animal influenza A viruses in MDCK-SIAT1 cells*

Virus subtype FRA
 HINT
No. viruses tested EC50, nmol/L, mean ± SD† No. viruses tested EC50, nmol/L, mean ± SD†
Avian origin
H5N6‡ 3 0.31 ± 0.19 – –
H6N1 1 0.12 1 0.48
H7N9 19 0.48 ± 0.32 9 1.44 ± 1.08
H9N2§ 1 0.18 1 0.53
H10N8
 1
 0.30
1
 0.63
Swine origin
H1N1¶ – – 3 0.72 ± 0.27
H1N1v – – 3 0.51 ± 0.12
H1N2v – – 9 1.19 ± 0.36
H3N2v
 –
 –
15
 0.86 ± 0.50
Reference viruses#
A/Illinois/08/2018 (H1N1)pdm09 PA-I38 2.12 – 1.75 ± 0.59
A/Illinois/37/2018 (H1N1)pdm09 PA-I38L
 14.96 (7-fold)** – 13.09 ± 3.56 (8-fold)**

*Both assays were conducted by using MDCK-SIAT1 cells. Details on viruses tested are in the Appendix. According to World Health Organization nomenclature, the swine-origin influenza viruses isolated from humans are named variant viruses (e.g., A[H1N1]v). EC50, 50% effective concentration; FRA, focus reduction assay; HINT, high-content imaging neutralization test; –, not tested.
†Mean ± SD or average of 2 test results.
‡One of 3 viruses was isolated from chicken (Appendix Table 1).
§Virus was isolated from chicken (Appendix Table 1).
¶All 3 viruses were isolated from swine (Appendix Table 2).
#A pair of seasonal influenza A(H1N1)pdm09 viruses were included in each test as reference viruses (12).
**Fold change to EC50 of virus carrying PA-I38L compared with sequence-matched control virus carrying PA-I38.

Main Article

References
  1. Asha  K, Kumar  B. Emerging influenza D virus threat: what we know so far! J Clin Med. 2019;8:E192. DOIPubMedGoogle Scholar
  2. Uyeki  TM, Katz  JM, Jernigan  DB. Novel influenza A viruses and pandemic threats. Lancet. 2017;389:2172–4. DOIPubMedGoogle Scholar
  3. Garten  RJ, Davis  CT, Russell  CA, Shu  B, Lindstrom  S, Balish  A, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 2009;325:197–201. DOIPubMedGoogle Scholar
  4. Njouom  R, Monamele  GC, Ermetal  B, Tchatchouang  S, Moyo-Tetang  S, McCauley  JW, et al. Detection of influenza C virus infection among hospitalized patients, Cameroon. Emerg Infect Dis. 2019;25:607–9. DOIPubMedGoogle Scholar
  5. Hu  Y, Lu  S, Song  Z, Wang  W, Hao  P, Li  J, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet. 2013;381:2273–9. DOIPubMedGoogle Scholar
  6. Hurt  AC. The epidemiology and spread of drug resistant human influenza viruses. Curr Opin Virol. 2014;8:22–9. DOIPubMedGoogle Scholar
  7. Furuta  Y, Komeno  T, Nakamura  T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad, Ser B, Phys Biol Sci. 2017;93:449–63. DOIPubMedGoogle Scholar
  8. DuBois  RM, Slavish  PJ, Baughman  BM, Yun  MK, Bao  J, Webby  RJ, et al. Structural and biochemical basis for development of influenza virus inhibitors targeting the PA endonuclease. PLoS Pathog. 2012;8:e1002830. DOIPubMedGoogle Scholar
  9. Hayden  FG, Sugaya  N, Hirotsu  N, Lee  N, de Jong  MD, Hurt  AC, et al.; Baloxavir Marboxil Investigators Group. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379:913–23. DOIPubMedGoogle Scholar
  10. Noshi  T, Kitano  M, Taniguchi  K, Yamamoto  A, Omoto  S, Baba  K, et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Res. 2018;160:109–17. DOIPubMedGoogle Scholar
  11. Omoto  S, Speranzini  V, Hashimoto  T, Noshi  T, Yamaguchi  H, Kawai  M, et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep. 2018;8:9633. DOIPubMedGoogle Scholar
  12. Gubareva  LV, Mishin  VP, Patel  MC, Chesnokov  A, Nguyen  HT, De La Cruz  J, et al. Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons. Euro Surveill. 2019;24:24. DOIPubMedGoogle Scholar
  13. Taniguchi  K, Ando  Y, Nobori  H, Toba  S, Noshi  T, Kobayashi  M, et al. Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil. Sci Rep. 2019;9:3466. DOIPubMedGoogle Scholar
  14. Koszalka  P, Tilmanis  D, Roe  M, Vijaykrishna  D, Hurt  AC. Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018. Antiviral Res. 2019;164:91–6. DOIPubMedGoogle Scholar
  15. Takashita  E, Morita  H, Ogawa  R, Nakamura  K, Fujisaki  S, Shirakura  M, et al. Susceptibility of influenza viruses to the novel cap-dependent endonuclease inhibitor baloxavir marboxil. Front Microbiol. 2018;9:3026. DOIPubMedGoogle Scholar

Main Article

1Preliminary results from this study were presented at the 6th International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group Conference; November 13–15, 2018; Rockville, Maryland, USA.

Page created: September 17, 2019
Page updated: September 17, 2019
Page reviewed: September 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external